Quick answer: People using GLP-1-based medications such as semaglutide (Ozempic, Wegovy or Rybelsus) or tirzepatide (Mounjaro) do not all need the same blood-test panel. For patients with type 2 diabetes, HbA1c, kidney function, urine albumin-to-creatinine ratio (UACR) and cardiovascular risk assessment are often especially important. Some patients also benefit from targeted investigations such as ApoB, lipoprotein(a), cystatin C, liver fibrosis testing, vitamin B12 or iron studies. The choice depends on the patient's disease, symptoms, other medication and the clinical question—not on the GLP-1 prescription alone. [1–3]
Medically reviewed by: Dr Shantakumar Muruda, MD (Medical Biochemistry), Founder & CEO, QXL Diagnostics, Bengaluru.
Research updated: 6 November 2026 · Reading time: approximately 18 minutes.
Clinical scope: Adult education; prescribed therapies only. This is not a drug-prescribing protocol.
At a glance: which tests matter most?#
| Clinical objective | First-line assessment | Specialist investigation when clinically indicated |
|---|---|---|
| Glycaemic response in diabetes | HbA1c, glucose and/or CGM | C-peptide with simultaneous glucose if diabetes classification is uncertain |
| Kidney health | Creatinine/eGFR; urine ACR in diabetes | Cystatin C and combined creatinine–cystatin C eGFR when muscle changes or precision matter |
| Atherosclerotic risk | Lipid profile, blood pressure and risk assessment | ApoB and a once-in-adulthood Lp(a) assessment |
| Suspected fatty liver and fibrosis | ALT, AST, platelets; FIB-4 | ELF test, transient elastography or hepatology assessment |
| Reduced food intake or deficiency symptoms | CBC and symptom-directed nutrition review | Ferritin/iron studies, B12 with MMA when equivocal, thiamine or other selected micronutrients |
| Possible heart failure | Symptoms, examination and ECG where appropriate | NT-proBNP and echocardiography |
| Loss of strength or fracture risk | Clinical function, nutrition, fracture-risk assessment | DXA; P1NP/CTX only in selected bone-specialist contexts |
| Severe abdominal pain or dehydration | Urgent medical evaluation | Lipase, kidney chemistry, electrolytes or hepatobiliary tests according to findings |
Key point: A more expensive panel is not necessarily a better panel. Precision diagnostics means selecting tests that can change clinical decisions.
What are GLP-1 receptor agonists and dual incretin medicines?#
GLP-1 (glucagon-like peptide-1) is an intestinal incretin hormone involved in post-meal glucose regulation and satiety. GLP-1 receptor agonists promote glucose-dependent insulin release, suppress inappropriate glucagon secretion during hyperglycaemia and influence appetite. They also delay gastric emptying to varying degrees. Semaglutide is a GLP-1 receptor agonist; tirzepatide acts at both GIP and GLP-1 receptors, so it is a dual incretin agonist rather than a GLP-1-only drug.
Brand names, drug formulations, approved indications and doses vary by country. A diabetes-labelled formulation is not automatically interchangeable with an obesity-labelled formulation. Medication must be prescribed and monitored by an appropriately qualified clinician. Hypoglycaemia is more likely when these medicines are combined with insulin or sulfonylureas. [2,4]
What does the strongest recent research actually show?#
The following outcomes come from different trial populations and cannot be directly compared as if the medicines were tested head-to-head.
| Study | Population and medicine | Major published finding | What the finding means for testing |
|---|---|---|---|
| SELECT (2023) | 17,604 adults with established CVD and overweight/obesity, without diabetes; semaglutide | Major cardiovascular events occurred in 6.5% versus 8.0% with placebo (HR 0.80) | Assess existing cardiovascular risk; weight loss does not replace lipid or risk-factor management. [5] |
| FLOW (2024) | 3,533 people with type 2 diabetes and CKD; semaglutide | 24% lower relative risk of the composite kidney/CV-death outcome (HR 0.76) | eGFR and urine ACR identify kidney impairment and help follow existing CKD. [6] |
| SOUL (2025) | 9,650 high-risk adults with type 2 diabetes; oral semaglutide | Major CV events: 12.0% versus 13.8% (HR 0.86) | Management extends beyond HbA1c alone. [7] |
| ESSENCE (2025) | MASH with fibrosis F2–F3; semaglutide | MASH resolution without fibrosis worsening: 62.9% vs 34.3%; fibrosis improvement without MASH worsening: 36.8% vs 22.4% | Target fibrosis risk, not just ALT; consider FIB-4 and second-line tests when appropriate. [8] |
| SYNERGY-NASH (2024) | 190 people with biopsy-proven MASH F2–F3; tirzepatide | MASH resolution: 44–62% across active groups versus 10% with placebo | Specialist liver assessment may be important in selected patients. [9] |
| SURPASS-CVOT (2025) | Type 2 diabetes and established ASCVD; tirzepatide vs dulaglutide | Tirzepatide met noninferiority, but primary-outcome superiority was not established | Avoid assuming that greater weight loss proves better outcomes for every endpoint. [10] |
| SURMOUNT-1 DXA analysis (2025) | Body-composition substudy; tirzepatide | Approximately 75% of weight lost was fat mass and 25% lean mass | Assess diet, strength and function; lean mass is not identical to skeletal muscle. [11] |
In the United States, semaglutide received an additional accelerated FDA approval for selected adults with noncirrhotic MASH and F2–F3 fibrosis in August 2025. This is a US regulatory decision and should not be presented as a blanket Indian indication; Indian prescribing must follow applicable Indian product approvals and guidance. [12]
Essential tests before or during treatment#
1. HbA1c and glucose: is diabetes control improving?#
HbA1c reflects average glycaemic exposure over approximately 2–3 months. In people with diabetes, HbA1c is commonly reassessed about every three months after treatment changes and less often when control is stable and targets are met. Individual treatment targets depend on age, comorbidities, hypoglycaemia risk and clinical priorities. Finger-stick glucose or continuous glucose monitoring may be essential when using insulin or sulfonylureas.
HbA1c can be misleading in anaemia, altered red-cell survival, recent transfusion or certain haemoglobin variants. Results must be interpreted in context; assay methodology and quality controls matter. Learn about QXL's HbA1c testing and browse the blood test directory.
2. Creatinine, eGFR, electrolytes and urine ACR: two sides of kidney health#
Serum creatinine and estimated GFR reflect kidney filtration; urine ACR detects albuminuria, an important marker of diabetic kidney damage. Both eGFR and urine ACR are recommended at least annually in adults with type 2 diabetes, with more frequent review for established kidney disease. [1]
| UACR (mg/g) | KDIGO albuminuria category |
|---|---|
| <30 | A1 — normal to mildly increased |
| 30–300 | A2 — moderately increased |
| >300 | A3 — severely increased |
An abnormal UACR often needs confirmation because fever, urinary infection, recent intense exercise and other conditions can transiently increase albuminuria. Major vomiting or diarrhoea may cause dehydration and acute kidney injury; clinicians may promptly check creatinine, sodium, potassium and bicarbonate, especially during initiation or escalation. See the kidney function test guide. [4]
3. Lipid profile: cardiovascular benefit is not the same as absence of residual risk#
Weight loss may improve several lipid parameters, but patients can retain cardiovascular risk because of inherited factors, diabetes, hypertension, smoking or established atherosclerosis. A standard lipid profile is foundational. See lipid profile testing in Bengaluru.
4. Liver function and FIB-4: identify fibrosis risk#
For people with type 2 diabetes or obesity and suspected MASLD (metabolic dysfunction-associated steatotic liver disease), liver risk stratification may be appropriate. FIB-4 is calculated from age, AST, ALT and platelets. A frequently used first-line threshold is 1.3 in adults within the applicable age group, but age-specific qualifications and clinical judgement are essential. Normal AST/ALT do not exclude clinically important fibrosis. [3]
In suitable patients with indeterminate or raised FIB-4, a clinician may request transient elastography or an accepted secondary blood-based assessment, such as ELF. See the liver function test service.
Advanced super-speciality tests: when do they add value?#
ApoB — atherogenic lipoprotein particle burden#
Each LDL, VLDL remnant and lipoprotein(a) particle typically carries one ApoB protein. ApoB therefore better reflects the number of atherogenic lipoprotein particles than LDL cholesterol alone in some patients. It is particularly useful where triglycerides are elevated, diabetes is present, or apparent LDL-C control does not align with overall cardiovascular risk. The 2026 US dyslipidaemia guideline supports selective ApoB testing, rather than a universal GLP-1-specific ApoB schedule. [13]
Read QXL's detailed ApoB versus LDL cholesterol guide and cardiovascular biomarker services.
Lipoprotein(a), or Lp(a) — inherited cardiovascular risk#
Lp(a) is predominantly genetically determined. A person may improve HbA1c and weight while retaining high Lp(a)-associated risk. The 2026 American guideline recommends measuring Lp(a) at least once in adulthood for ASCVD risk assessment. A concentration of 125 nmol/L or higher is considered a risk-enhancing factor in that guideline. Do not use a universal fixed conversion between nmol/L and mg/dL, because apo(a) isoforms affect mass-based measurement. Routine serial Lp(a) testing is rarely necessary. [13]
Cystatin C — when creatinine estimates may be distorted by muscle changes#
Significant weight reduction can be accompanied by loss of lean tissue. When creatinine production decreases, creatinine-based eGFR can change without a proportionate improvement in true filtration. Cystatin C provides another filtration marker. A combined creatinine–cystatin C eGFR may be useful when a more accurate estimate could affect treatment, CKD staging or clinical interpretation. It is not immune to non-kidney influences, such as inflammation or thyroid dysfunction. [1]
Learn more in QXL's advanced kidney and liver biomarkers article.
Enhanced Liver Fibrosis (ELF) — a second-line fibrosis biomarker panel#
ELF combines hyaluronic acid (HA), PIIINP (procollagen III amino-terminal propeptide) and TIMP-1 (tissue inhibitor of metalloproteinases-1) in a validated score related to extracellular-matrix turnover. Its purpose is to help stratify liver-fibrosis risk in selected patients with suspected or known MASLD/MASH, often after FIB-4 screening. It is not an ordinary liver function test and it is not automatically required for all semaglutide users. A result does not independently prove a particular fibrosis stage. [3,8]
Service note: Confirm test availability, referral laboratory, specimen conditions, clinical reporting and NABL accreditation scope before booking an ELF or other advanced send-out assay.
NT-proBNP — where heart failure is suspected#
NT-proBNP helps assess suspected or established heart failure; it is not a routine weight-loss-treatment marker. It may be appropriate for breathlessness, oedema, reduced exercise tolerance or clinician-directed heart-failure follow-up. Obesity can lower natriuretic peptide concentrations, so interpret results alongside symptoms and echocardiography. High-sensitivity troponin is for relevant myocardial injury assessment—not routine GLP-1 surveillance.
Advanced nutritional investigations — for rapid loss, symptoms or high-risk dietary intake#
The ADA 2026 guidance emphasises adequate protein and micronutrient intake during intentional weight loss and recommends screening for deficiencies when weight loss exceeds 20% or occurs at a rapid rate such as more than 4% per month, based on clinical judgement. There is no universal schedule for broad micronutrient panels. [2]
| Clinical trigger | Possible laboratory investigations | Caveat |
|---|---|---|
| Fatigue, anaemia, restricted diet | CBC, ferritin and iron/transferrin saturation | Ferritin rises with inflammation; investigate blood loss where relevant |
| Neuropathy or borderline B12, especially with metformin | Serum B12; methylmalonic acid (MMA) or active B12 selectively | MMA can increase with reduced kidney function |
| Bone disease, fracture risk or inadequate intake | 25-OH vitamin D, calcium, phosphate, PTH if indicated | Vitamin D screening is not automatically necessary for everyone |
| Prolonged vomiting or marked malnutrition | Electrolytes, magnesium and thiamine assessment where relevant | Suspected Wernicke encephalopathy requires urgent treatment; never wait for a test |
| Unexplained hair loss or deficiency signs | CBC, ferritin, TSH and selected zinc testing | Do not assume every symptom is caused by the GLP-1 drug |
See QXL's vitamin B12 deficiency clinical guide.
C-peptide and GAD65, IA-2 or ZnT8 antibodies — when diabetes classification is uncertain#
Not every adult with obesity and diabetes has typical type 2 diabetes. C-peptide, interpreted with simultaneous glucose and kidney function, can help assess endogenous insulin production. Islet antibodies may be useful where an autoimmune form of diabetes is suspected. These are diagnostic clarification tools, not mandatory monthly tests for tirzepatide or semaglutide users.
Bone turnover markers and body composition — selected specialist applications#
A 2025 DXA substudy of SURMOUNT-1 found that approximately 75% of lost body weight was fat mass and 25% lean mass. Lean mass includes components beyond skeletal muscle. No blood test alone measures muscle mass or sarcopenia. Dietary review, resistance exercise, strength testing and, when indicated, DXA body composition are more informative. [11]
P1NP (bone formation) and CTX (bone resorption) can assist selected osteoporosis evaluations or osteoporosis-treatment monitoring; they are not validated as universal GLP-1 safety tests. For some patients, DXA, liver elastography or ultrasound from an appropriately qualified preventive radiology/imaging provider complements pathology. These are separate diagnostic modalities and should not be represented as QXL in-house imaging services unless actually available.
Which tests should NOT be sold as routine monthly GLP-1 monitoring?#
The following are not universally indicated merely because a person uses a GLP-1 medication: monthly amylase/lipase, calcitonin screening for thyroid cancer, broad sex-hormone or cortisol panels, fasting insulin/HOMA-IR, comprehensive cytokine panels, leptin/adiponectin, large vitamin and trace-element panels, repeated Lp(a), bone-turnover markers, or commercial microbiome/metabolomic profiles. These may have different diagnostic, specialist or research roles but should not be bundled indiscriminately. [2,4]
Pancreatitis and thyroid safety, without unnecessary screening#
Persistent severe abdominal pain, especially pain radiating to the back, can indicate acute pancreatitis and needs urgent clinical assessment; lipase is useful when pancreatitis is suspected. Asymptomatic elevations in pancreatic enzymes do not by themselves diagnose pancreatitis. Routine serial lipase/amylase testing in well patients is not generally recommended. [4]
Semaglutide and tirzepatide prescribing information includes a boxed warning about thyroid C-cell tumours observed in rodents and contraindications involving personal/family medullary thyroid carcinoma or MEN2. TSH and free T4 test thyroid function but do not screen for medullary thyroid cancer. Routine calcitonin or thyroid ultrasound solely for GLP-1 use has uncertain value. [4]
New severe vomiting with reduced urine output, suspected hypoglycaemia, jaundice, or sudden visual loss requires prompt medical assessment—not a routine online checkup.
A practical timeline for testing#
| Treatment stage | Clinical monitoring | Laboratory approach |
|---|---|---|
| Before treatment | Indication, medical history, medicines, kidney/heart/liver disease, nutrition, weight and blood pressure | Select baseline HbA1c/glucose, kidney function, lipids and other tests based on indication; urine ACR for diabetes |
| Weeks 2–8 / dose escalation | Nausea, vomiting, hydration, appetite and hypoglycaemia risk | Repeat creatinine/electrolytes promptly if significant GI symptoms or other risks—not automatically in everyone |
| Around 3 months | Weight trajectory, eating pattern, diabetes response and treatment tolerance | HbA1c in people with diabetes after a change; other testing if it will affect care |
| 6–12 months | Cardiovascular and kidney risk, liver disease, nutritional adequacy, physical function | Individualised re-evaluation; annual eGFR and UACR in type 2 diabetes, more often with CKD |
| Long term | Sustainable treatment, complications, health outcomes | Repeat tests according to established disease and guideline-based care, not a fixed universal panel |
For a wider assessment, patients and clinicians may compare QXL's health checkup packages, including the Q-Screen Diabetes Package. A large preventive package should not be assumed to replace the indication-specific investigations described here.
AI-assisted precision diagnostics: what laboratory technology can and cannot do#
Advanced pathology and precision diagnostics depend on more than the total number of parameters tested. Standardised methods, sample traceability, appropriate interpretation, internal quality controls and external quality assessment all support trustworthy results.
AI-assisted laboratory workflows can support delta-check alerts, quality-control reviews, prioritisation and administrative decision support. They should not replace authorised medical review, clinical judgement or method validation. AI-driven health screenings and predictive risk models must be evaluated for bias, accuracy, intended population and appropriate oversight before any clinical deployment.
This matters especially when a treatment changes weight, creatinine generation or metabolic biomarkers: an unusual result must be interpreted medically, not converted into an automatic diagnosis by an algorithm.
QXL Diagnostics is a doctor-led, NABL-accredited medical laboratory in Bengaluru. Its published laboratory information identifies ISO 15189:2022 accreditation under certificate MC-6849. Accreditation applies to the laboratory's defined scope of tests, not automatically every advanced or referral test discussed in this article.
How can patients in Bengaluru arrange appropriate tests?#
Discuss your treatment, symptoms, diabetes history and any recent abnormal results with your treating physician. Bring the prescription or clinician-recommended list rather than ordering every speciality biomarker.
QXL's live services include individual blood tests, speciality diagnostic services, health checkup packages and home blood sample collection across eligible Bengaluru localities. You can book a laboratory test online or contact +91 9964 639 639. Confirm fasting, collection conditions, price and expected turnaround time for each investigation; some advanced tests may require referral processing or centre collection.
QXL Diagnostics — Super Speciality Diagnostic Laboratory
Kengeri Main Laboratory: 3rd Floor, SLN Complex, Mysore Road, Bengaluru 560060.
Find QXL locations · Book blood tests · WhatsApp QXL
Frequently asked questions about GLP-1 blood tests#
1. What blood tests are needed before starting Ozempic or Mounjaro?#
A clinician may assess HbA1c or glucose, creatinine/eGFR, lipid profile and other tests based on the reason for treatment and underlying disease. Urine ACR is important for many people with type 2 diabetes. No identical extensive panel is mandatory for everyone.
2. How often should HbA1c be tested while taking GLP-1 medication?#
For people with diabetes, HbA1c is commonly checked approximately every three months after treatment changes, and at least twice a year when stable and meeting targets. Patients using insulin or sulfonylureas may need more frequent glucose monitoring.
3. Should GLP-1 users test kidney function?#
Kidney assessment is important in people with diabetes, CKD or dehydration risk. Creatinine/eGFR and urine ACR answer different questions. Persistent vomiting or diarrhoea warrants earlier medical review and possible renal/electrolyte tests.
4. Is ApoB better than LDL cholesterol for GLP-1 patients?#
ApoB can reveal residual atherogenic lipoprotein particle burden when LDL-C underestimates risk, especially with diabetes or high triglycerides. It complements rather than automatically replaces standard lipid assessment and is not a universal GLP-1 response test.
5. Do I need a lipoprotein(a) test during weight-loss treatment?#
The 2026 American dyslipidaemia guideline recommends at least one adult Lp(a) measurement for cardiovascular risk assessment. It identifies inherited risk; repeated testing every few months is generally unnecessary.
6. Why might a doctor request cystatin C after major weight loss?#
Muscle loss can alter creatinine production and therefore creatinine-based eGFR. Cystatin C, used with creatinine in a combined eGFR equation, can help when a more precise kidney estimate would change medical decisions.
7. What is the ELF test, and does every GLP-1 patient need it?#
The Enhanced Liver Fibrosis (ELF) score combines HA, PIIINP and TIMP-1 to help assess liver fibrosis in selected at-risk patients. It is not recommended as a routine blood test for everyone taking semaglutide or tirzepatide.
8. Should I check vitamin B12, vitamin D and iron while taking Mounjaro?#
These tests may be useful with restricted intake, rapid weight loss, anaemia, neuropathy, metformin use, bone-health concerns or other indications. Comprehensive vitamin testing is not mandatory for all users.
9. Is monthly lipase testing required to prevent pancreatitis?#
No. Routine lipase or amylase screening of asymptomatic patients is not generally recommended. Severe persistent abdominal pain or repeated vomiting requires urgent clinical evaluation, with lipase testing when pancreatitis is suspected.
10. Can blood tests detect muscle loss from GLP-1 treatment?#
No routine blood test directly quantifies muscle loss. Diet and function assessment, strength testing and body-composition methods such as DXA are more informative in selected patients.
Conclusion#
The goal of GLP-1 monitoring is better metabolic and organ health—not more tests. Core assessments such as HbA1c, eGFR, urine ACR and lipids remain crucial for many patients with type 2 diabetes. Advanced ApoB, Lp(a), cystatin C, ELF, nutritional or endocrine investigations can be valuable when linked to a specific clinical indication. A personalised, clinician-directed approach protects patients from missed risks and unnecessary investigations alike.
Research and clinical references#
- American Diabetes Association. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026.
- American Diabetes Association. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care—2026.
- American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities—2026.
- U.S. National Library of Medicine DailyMed. Tirzepatide (Mounjaro) prescribing information, 2026.
- SELECT investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.
- FLOW investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024.
- SOUL investigators. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025.
- ESSENCE investigators. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. N Engl J Med. 2025.
- SYNERGY-NASH investigators. Tirzepatide for MASH with Liver Fibrosis. N Engl J Med. 2024.
- SURPASS-CVOT investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide. N Engl J Med. 2025.
- SURMOUNT-1 investigators. Body composition changes during weight reduction with tirzepatide. Diabetes Obes Metab. 2025.
- U.S. Food and Drug Administration. FDA approves treatment for MASH. August 2025.
- American Heart Association/American College of Cardiology. 2026 guideline on management of dyslipidaemia.
- Harrison's Principles of Internal Medicine. 22nd edition, 2025. Obesity and diabetes chapters. Textbook reference framework; primary trial and 2026 guideline claims are supported by the linked sources above.
Medical disclaimer: This article is educational, is not a prescription, and does not replace individual medical assessment. Severe abdominal pain, dehydration, confusion, serious hypoglycaemia, chest pain or sudden visual loss requires urgent care. Not all investigations listed are necessary, available in-house or within the laboratory's accredited scope. Drug indications and approvals vary by jurisdiction.
Medical & Laboratory Disclaimer
This clinical article is published solely for patient education and informational purposes. It does not replace personal medical advice, clinical diagnosis, prenatal genetic counselling, or obstetric supervision. Appropriate laboratory investigations must be determined by your treating physician based on your personal health history.
Dr Shantakumar Muruda, MD (Medical Biochemistry)
Head of Clinical Biochemistry & Quality Management, QXL Diagnostics Bengaluru (NABL Accredited Laboratory MC-6849). Trained Lead Assessor for ISO 15189:2022 medical laboratory standards.
QXL Clinical Editorial Commitment: Every health guide, biomarker explanation, and screening schedule published on this portal undergoes rigorous clinical review by qualified MD pathologists and biochemists to ensure adherence to peer-reviewed evidence (ACOG, WHO, ICMR) and laboratory diagnostic accuracy.
